Literature DB >> 1318074

Gene transfer in human lymphocytes using a vector based on adeno-associated virus.

C A Muro-Cacho1, R J Samulski, D Kaplan.   

Abstract

Adeno-associated virus is a nonpathogenic, dependent parvovirus that integrates at a specific site in human chromosome 19. We have used the inverted terminal repeats of the virus, which mediate integration, to establish a vector for gene transfer in human lymphocytes. A neomycin resistance gene has been stably introduced into nontransformed human T-cell clones and a subsequent analysis of the functional properties of the infected clone revealed no detectable alterations. Rescue and replication of the wild-type virus was accomplished with adenovirus superinfection; however, the vector was not rescued and did not replicate by this procedure, indicating the stability of the integrated vector and demonstrating an additional level of safety incorporated in its construction. An adeno-associated virus-based vector represents an alternative to retroviruses for gene therapy in lymphocytes.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1318074     DOI: 10.1097/00002371-199205000-00001

Source DB:  PubMed          Journal:  J Immunother (1991)        ISSN: 1053-8550


  9 in total

Review 1.  Vectors for cancer gene therapy.

Authors:  J Zhang; S J Russell
Journal:  Cancer Metastasis Rev       Date:  1996-09       Impact factor: 9.264

2.  Functional measurement of hepatitis C virus core-specific CD8(+) T-cell responses in the livers or peripheral blood of patients by using autologous peripheral blood mononuclear cells as targets or stimulators.

Authors:  S H Fang; B L Chiang; M H Wu; H Iba; M Y Lai; P M Yang; D S Chen; L H Hwang
Journal:  J Clin Microbiol       Date:  2001-11       Impact factor: 5.948

3.  Cellular recombination pathways and viral terminal repeat hairpin structures are sufficient for adeno-associated virus integration in vivo and in vitro.

Authors:  C C Yang; X Xiao; X Zhu; D C Ansardi; N D Epstein; M R Frey; A G Matera; R J Samulski
Journal:  J Virol       Date:  1997-12       Impact factor: 5.103

Review 4.  Human cancer and gene therapy.

Authors:  G Schmidt-Wolf; I G Schmidt-Wolf
Journal:  Ann Hematol       Date:  1994-12       Impact factor: 3.673

5.  Potent inhibition of human immunodeficiency virus type 1 in primary T cells and alveolar macrophages by a combination anti-Rev strategy delivered in an adeno-associated virus vector.

Authors:  R T Inouye; B Du; D Boldt-Houle; A Ferrante; I W Park; S M Hammer; L Duan; J E Groopman; R J Pomerantz; E F Terwilliger
Journal:  J Virol       Date:  1997-05       Impact factor: 5.103

Review 6.  Gene therapy for PNET.

Authors:  C Raffel
Journal:  J Neurooncol       Date:  1996-07       Impact factor: 4.130

7.  Development of animal models for adeno-associated virus site-specific integration.

Authors:  G Rizzuto; B Gorgoni; M Cappelletti; D Lazzaro; I Gloaguen; V Poli; A Sgura; D Cimini; G Ciliberto; R Cortese; E Fattori; N La Monica
Journal:  J Virol       Date:  1999-03       Impact factor: 5.103

8.  Adeno-associated virus (AAV) Rep proteins mediate complex formation between AAV DNA and its integration site in human DNA.

Authors:  M D Weitzman; S R Kyöstiö; R M Kotin; R A Owens
Journal:  Proc Natl Acad Sci U S A       Date:  1994-06-21       Impact factor: 11.205

9.  Adeno-associated virus 2-mediated high efficiency gene transfer into immature and mature subsets of hematopoietic progenitor cells in human umbilical cord blood.

Authors:  S Z Zhou; S Cooper; L Y Kang; L Ruggieri; S Heimfeld; A Srivastava; H E Broxmeyer
Journal:  J Exp Med       Date:  1994-06-01       Impact factor: 14.307

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.